

CS/NSE&BSE/PR/2021-22
June 10, 2021

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: News Release

.....

With reference to the above subject, please find enclosed News Release of our company titled **“CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG.”**

In this connection, please further note that the **TRADING WINDOW** for dealing in the securities of the company which was closed from 01st April, 2021 as per PIT Code of the Company stands extended till 13th June, 2021. The trading window will be opened from 14th June, 2021.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited

News Release

CSIR-IICT and SUVEN Pharmaceuticals Ltd., joined hands for the process technology transfer and manufacture of anti COVID drugs Molnupiravir and 2-DG

HYDERABAD, INDIA (10 June' 2021) Suven Pharmaceuticals Ltd., (SPL), CSIR-Indian Institute of Chemical Technology, Hyderabad and CSIR-National Institute of Interdisciplinary Science & Technology, Thiruvananthapuram have entered into an agreement for the process technology transfer and manufacturing of the anti COVID drug, Molnupiravir and 2-DG. It is a related party transaction as one of our Independent Directors Dr S Chandrasekhar is the Director of CSIR-IICT, Hyderabad. The agreements between the parties involve a total fee of Rs 8 lakh plus taxes for the grant of the licenses on non-exclusive basis to SPL.

Molnupiravir, the antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours according to the study recently published in the journal Nature Microbiology. The drug could be a game changer in mitigation of SARS-CoV-2 virus.

The synthetic process know how for Molnupiravir was sourced from CSIR-NIIST and scale up process was successfully carried out by CSIR-IICT. The complete technology know how will be transferred and SPL in turn will manufacture and launch in the domestic market as an effective medication for COVID infected patients subject to regulatory approvals.

As per the agreement, CSIR IICT also would provide the process know how for the manufacture of new anti COVID drug 2-DG to treat moderately and severely COVID infected patients to reduce their oxygen dependency.

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited